Vanguard Group Inc. Raises Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

Vanguard Group Inc. lifted its holdings in Orthofix Medical Inc. (NASDAQ:OFIX) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,126,785 shares of the medical device company’s stock after buying an additional 12,286 shares during the quarter. Vanguard Group Inc. owned 5.57% of Orthofix Medical worth $37,134,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OFIX. R Squared Ltd acquired a new stake in Orthofix Medical in the 4th quarter valued at about $50,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Orthofix Medical in the fourth quarter valued at approximately $112,000. Inceptionr LLC purchased a new position in shares of Orthofix Medical during the 4th quarter worth approximately $279,000. Fox Run Management L.L.C. purchased a new position in shares of Orthofix Medical during the 4th quarter worth approximately $327,000. Finally, Franklin Resources Inc. raised its position in shares of Orthofix Medical by 37.4% during the 3rd quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company’s stock worth $337,000 after purchasing an additional 5,702 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on OFIX shares. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a report on Tuesday, February 25th. Roth Mkm reaffirmed a “buy” rating and issued a $22.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $24.00 price target on shares of Orthofix Medical in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Orthofix Medical has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.

Insider Buying and Selling

In related news, insider Lucas Vitale sold 4,287 shares of Orthofix Medical stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total transaction of $71,164.20. Following the transaction, the insider now directly owns 135,317 shares of the company’s stock, valued at $2,246,262.20. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Julie Andrews sold 4,655 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the sale, the chief financial officer now owns 28,312 shares in the company, valued at $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,081 shares of company stock valued at $174,197 in the last quarter. Company insiders own 2.60% of the company’s stock.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $13.67 on Monday. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $533.43 million, a price-to-earnings ratio of -4.37 and a beta of 0.99. Orthofix Medical Inc. has a twelve month low of $12.08 and a twelve month high of $20.73. The business has a 50 day simple moving average of $16.77 and a 200-day simple moving average of $17.25.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.